Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2008

01-12-2008 | Short Report

Low allelic heterogeneity in a sample of Mexican patients with classical galactosaemia

Authors: J. Velázquez-Aragón, M. A. Alcántara-Ortigoza, M. Vela-Amieva, S. Monroy, V. Martínez-Cruz, C. Todd-Quiñones, A. González-del Angel

Published in: Journal of Inherited Metabolic Disease | Special Issue 2/2008

Login to get access

Summary

Classical galactosaemia is an autosomal recessive disease of galactose metabolism caused by a deficiency of the enzyme galactose-1-phosphate uridyltransferase (GALT). Galactosaemia is not included in the neonatal screening programme in Mexico and it is necessary to implement methodologies for prompt diagnosis of these patients to establish treatment. To date, more than 190 mutations in the GALT gene have been reported, most in caucasian populations, but there have been no reports of mutations in Latin-American populations. We report here the mutational spectrum in 19 Mexican galactosaemic patients. The most frequent mutations were p.Q188R, p.N314D and IVS2-2A>G, which together represented 71% of detected mutations. The mutation IVS2-2A>G, which has been detected only in Hispanics, was thought to generate a null allele; we identified one patient with a homozygous IVS2-2A>G mutation who showed a mild deficiency of enzyme value in erythrocytes. One patient homozygous for Duarte 2 (p.N314D, IVS5+62G>A) is probably due to a partial uniparental disomy of chromosome 9. In addition, a novel mutation c.336T>C (p.S112R) was detected in one patient with severe enzymatic deficiency. Despite the small number of patients studied, our results suggest that classical galactosaemia shows low allelic heterogeneity in Mexican patients, in contrast what is observed in other Mendelian disorders such as cystinosis or autosomal dominant hypercholesterolaemia. This low allelic heterogeneity might be explained by a “population of origin” effect in the central region of Mexico, as has been described for phenylketonuria.
Literature
go back to reference Alcántara-Ortigoza MA, Belmont-Martínez L, Vela-Amieva M, González-del Angel A (2008) Analysis of the CTNS gene in nephropathic cystinosis Mexican patients: report of four novel mutations and identification of a false positive 57-kb deletion genotype with LDM-2/exon 4 multiplex PCR assay. Genet Test 12: 409–414. doi:10.1089/gte.2008.0014.PubMedCrossRef Alcántara-Ortigoza MA, Belmont-Martínez L, Vela-Amieva M, González-del Angel A (2008) Analysis of the CTNS gene in nephropathic cystinosis Mexican patients: report of four novel mutations and identification of a false positive 57-kb deletion genotype with LDM-2/exon 4 multiplex PCR assay. Genet Test 12: 409–414. doi:10.​1089/​gte.​2008.​0014.PubMedCrossRef
go back to reference Hirokawa H, Okano Y, Asada M, Fujimoto A, Suyama I, Isshiki G (1999) Molecular basis for phenotypic heterogeneity in galactosaemia: prediction of clinical phenotype from genotype in Japanese patients. Eur J Hum Genet 7: 757–764. doi:10.1038/sj.ejhg.5200368.PubMedCrossRef Hirokawa H, Okano Y, Asada M, Fujimoto A, Suyama I, Isshiki G (1999) Molecular basis for phenotypic heterogeneity in galactosaemia: prediction of clinical phenotype from genotype in Japanese patients. Eur J Hum Genet 7: 757–764. doi:10.​1038/​sj.​ejhg.​5200368.PubMedCrossRef
go back to reference Lisker R, Ramírez E, Babinsky V (1996) Genetic structure of autochthonous populations of Meso-America: Mexico. Hum Biol 68: 395–404.PubMed Lisker R, Ramírez E, Babinsky V (1996) Genetic structure of autochthonous populations of Meso-America: Mexico. Hum Biol 68: 395–404.PubMed
go back to reference Márquez-Morfín L (1993) La evaluación cuantitativa de la población novohispana siglos XVI al XVII. In: El poblamiento de México Vol. 2: El México Colonial. Mexico City: Secretaría de Gobernación, Consejo Nacional de Población, 36–63. Márquez-Morfín L (1993) La evaluación cuantitativa de la población novohispana siglos XVI al XVII. In: El poblamiento de México Vol. 2: El México Colonial. Mexico City: Secretaría de Gobernación, Consejo Nacional de Población, 36–63.
go back to reference Ng WG, Xu YK, Kaufman FR, et al (1994) Biochemical and molecular studies of 132 patients with galactosemia. Hum Genet 94: 359–363.PubMed Ng WG, Xu YK, Kaufman FR, et al (1994) Biochemical and molecular studies of 132 patients with galactosemia. Hum Genet 94: 359–363.PubMed
go back to reference Podskarbi T, Kohlmetz T, Gathof S, et al (1996) Molecular characterization of Duarte-1 and Duarte-2 variants of galactose-1-phosphate uridyltransferase. J Inherit Metab Dis 19: 638–644. doi:10.1007/BF01799840.PubMedCrossRef Podskarbi T, Kohlmetz T, Gathof S, et al (1996) Molecular characterization of Duarte-1 and Duarte-2 variants of galactose-1-phosphate uridyltransferase. J Inherit Metab Dis 19: 638–644. doi:10.​1007/​BF01799840.PubMedCrossRef
Metadata
Title
Low allelic heterogeneity in a sample of Mexican patients with classical galactosaemia
Authors
J. Velázquez-Aragón
M. A. Alcántara-Ortigoza
M. Vela-Amieva
S. Monroy
V. Martínez-Cruz
C. Todd-Quiñones
A. González-del Angel
Publication date
01-12-2008
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue Special Issue 2/2008
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-008-0905-y

Other articles of this Special Issue 2/2008

Journal of Inherited Metabolic Disease 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.